Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy

Journal of Clinical Oncology

Volumn 16, Issue 4, 1998, Pages 1568-1573

  Gralla, Richard J ^a   Navari, Rudolph M ^a   Hesketh, Paul J ^a   Popovic, William ^a   Strupp, John ^a   Noy, Jose ^a   Einhorn, Lawrence ^a   Ettinger, David ^a   Bushnell, William ^a   Friedman, Carl ^a  

^a Ochsner Cancer Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DEXAMETHASONE; GRANISETRON; METHYLPREDNISOLONE; ONDANSETRON;

ADULT; AGED; ANOREXIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VOMITING;

EID: 0031900165     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.4.1568     Document Type: Article

References (29)

1. Chevallier B: Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. Eur J Cancer 26:S33-S36, 1990 (suppl 1)
2. Hesketh PJ, Murphy WK, Lester EP, et al: GR 38032 (GR-C507/75): A novel compound effective in the prevention of acute cisplatin-induced emesis. J Clin Oncol 7:700-705, 1989
3. 3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy - A randomized study. Eur J Cancer 29A: 1669-1672, 1993
4. Kris MG, Gralla RJ, Clark RA, et al: Dose ranging evaluation of the serotonin antagonist GR-507/75 (GR38032F) when used as an antiemetic in patients receiving cancer chemotherapy. J Clin Oncol 6:659-662, 1988
5. Marty M: A comparison of granisetron as a single agent with conventional combination antiemetic therapies in the treatment of cytostatic-induced emesis. Eur J Cancer 28A:S12-S16, 1992 (suppl 1)
6. Navari RM, Kaplan HG, Gralla RJ, et al: Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol 12:2204-2210, 1994
7. Riviere A: Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. Br J Cancer 69:967-971, 1994
8. Soukop M: A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. Eur J Cancer 26:S15-S19, 1990 (suppl 1)
9. Chevallier B: The control of acute cisplatin-induced emesis - A comparative study of granisetron and combination regimen of high-dose metoclopramide and dexamethasone. Br J Cancer 68:176-180, 1993
10. De Mulder PHM, Seynaeve C, Vermerken JB, et al: Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 113:834-840, 1990
11. Gralla RJ, Rittenberg CN, Lettow LA, et al: A unique all-oral, single-dose, combination antiemetic regimen with high efficacy and marked cost saving potential. Proc Am Soc Clin Oncol 14:526, 1995 (abstr 1730)
12. Hainsworth J, Harvey W, Pendergrass K, et al: A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol 9:721-728, 1991
13. 3 (serotonin) antagonist ondansetron (GR38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 322:816-821, 1990
14. 3 antagonist, versus a standard antiemetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. Eur J Cancer 26:S28-S32, 1990 (suppl 1)
15. Soukop M: A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Support Care Cancer 2:177-183, 1994
16. Perez EA, Chawla SP, Kaywin PK, et al: Efficacy and safety of oral granisetron versus IV ondansetron in prevention of moderately emetogenic chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol 16:43a, 1997 (abstr 149)
17. Gebbia V, Cannata G, Testa A, et al: Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Cancer 74:1945-1952, 1994
18. Italian Group for Antiemetic Research: Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 6:805-810, 1995
19. Martoni S, Angelelli B, Guaraldi M, et al: Granisetron (GRA) vs. ondansetron (OND) in the prevention of cisplatinum-induced emesis: An open randomized cross-over study. Proc Am Soc Clin Oncol 13:431, 1994 (abstr 1481)
20. Navari RM, Gandara D, Hesketh P, et al: Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 13:1242-1248, 1995
21. Noble A, Bremmer K, Goedhals L, et al: A double blind, randomized, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: Assessment of efficacy, safety and patient preference. Eur J Cancer Clin Oncol 30A: 1083-1088, 1994
22. Heron JF: Single-agent oral granisetron for the prevention of acute cisplatin-induced emesis: A double-blind, randomized comparison with granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone. Semin Oncol 22:24-30, 1995 (suppl 10)
23. Heron JF, Goedhals L, Jordaan JP, et al: Oral granisetron alone and in combination with dexamethasone: A double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. Ann Oncol 5:579-584, 1994
24. Andrews PLR, Hawthorn J: The neurophysiology of vomiting. Baillieres Clin Gastroenterol 2:141-168, 1988
25. Borison HL, McCarthy LE: Neuropharmacology of chemotherapy-induced emesis. Drugs 25:8-17, 1983 (suppl 1)
26. Carpenter DO: Neural mechanisms of emesis. Can J Physiol Pharmacol 68:230-236, 1988
27. Seynaeve C, De Mulder PHM, Verweij J: Pathophysiology of cytotoxic drug-induced emesis: Far from crystal-clear. Pharm Weekbl 13:1-6, 1991
28. Andrews PLR: The pharmacologic profile of granisetron (Kytril). Semin Oncol 21:3-9, 1994
29. Goldwater SH, Neal-Janifer A, Milkovich G, et al: Smoothing the path for IV-to-oral conversion. Am J Health Syst Pharm 54:200-205, 1997